Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 654K | 2M |
| Gross Profit | 0 | 0 | 0 | 654K | 2M |
| Operating Income | 0 | -106M | -69M | -61M | -51M |
| EBITDA | 0 | -96M | -64M | -58M | -51M |
| Net Income | -100M | -98M | -66M | -59M | -51M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$4.70
-3.89% today
1Y Change
+13.64%
Window
Jun 26, 2025 → Jun 16, 2026
Coverage: 244 bars · Jun 26, 2025 → Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Lexeo Therapeutics, Inc. Common Stock (LXEO) is a Healthcare stock with a market cap of $430.00M and listed on NASDAQ. The stock last traded around $4.70 and up 13.6% across the available one-year price window (Jun 26, 2025 → Jun 16, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +39.8%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +39.8%, free cash flow -21.2% with operating margin 0.0% and ROIC -42.9%. Stock Foundry combines LXEO price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
LXEO
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
LXEO Max Drawdown
-61.15%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for LXEO and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$1.7M
+153.4% YoY
FY Net Income
-$50.6M
+14.6% YoY
Free Cash Flow
-$44.4M
+20.0% YoY
Revenue Growth
+0.0%
EPS Growth
+39.8%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 654K | 2M |
| Gross Profit | 0 | 0 | 0 | 654K | 2M |
| Operating Income | 0 | -106M | -69M | -61M | -51M |
| EBITDA | 0 | -96M | -64M | -58M | -51M |
| Net Income | -100M | -98M | -66M | -59M | -51M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 63M | 35M | 121M | 77M | 136M |
| Total Assets | 269M | 147M | 140M | 97M | 137M |
| Total Liabilities | 22M | 30M | 26M | 210M | 192M |
| Shareholder Equity | 247M | 117M | 114M | -113M | -56M |
| Total Debt | 8M | 10M | 12M | 13M | 0 |
| Net Debt | -55M | -25M | -110M | -64M | -136M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
44M
+19.0% YoY
Capital Expenditures
188K
+79.1% YoY
Free Cash Flow
44M
+20.0% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-67.3%
Debt / Equity
0.03x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.